Impact of acute-on-chronic liver failure and decompensated liver cirrhosis on psychosocial burden and quality of life of patients and their close relatives.


Journal

Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626

Informations de publication

Date de publication:
13 Jan 2020
Historique:
received: 06 09 2019
accepted: 29 12 2019
entrez: 15 1 2020
pubmed: 15 1 2020
medline: 17 3 2020
Statut: epublish

Résumé

Patients with liver cirrhosis often suffer from complications such as ascites, gastrointestinal bleeding, and infections, resulting in impaired quality of life. Frequently, the close relatives of patients also suffer from a lower quality of life in chronic diseases. In recent years, acute-to-chronic liver failure has been defined as a separate entity with high mortality. Often several organs are affected which makes intensive care therapy necessary. Little is known about the influence of acute-on-chronic-liver failure (ACLF) on the quality of life of patients and the psychosocial burden on close relatives. The purpose of this prospective study is to investigate the influence of decompensated liver cirrhosis and the onset of ACLF of the patient's' quality of life and the psychosocial burden of close relatives. In this non - randomized prospective cohort study a total of 63 patients with acute decompensation of liver cirrhosis and hospital admission were enrolled in the study. To assess the quality of life of patients, the disease specific CLDQ questionnaire was assessed. In addition. Quality of life and psychosocial burden of first degree relatives was measured using the generic SF-36 questionnaire as well as the Zarit Burden Score. 21 of the 63 patients suffered from ACLF. Patients with ACLF showed a lower quality of life in terms of worries compared to patients with only decompensated liver cirrhosis (3,57 ± 1,17 vs. 4,48 ± 1,27; p value: 0,008) and increased systemic symptoms (3,29 ± 1,19 vs. 4,48 ± 1,58; p value: 0,004). The univariate analysis confirmed the link between the existence of an ACLF and the concerns of patients. (p value: 0,001). The organ failure score was significantly associated with overall CLDQ scores, especially with worries and systemic symptoms of patients. Interestingly the psychosocial burden and quality of life of close relative correlates with patient's quality of life and was influenced by the onset of an acute-on-chronic liver failure. Patients with decompensated liver cirrhosis suffer from impaired quality of life. In particular, patients with ACLF have a significantly reduced quality of life. The extent of the psychosocial burden on close relative correlates with poor quality of life in patients with decompensated liver disease and is influenced by the existence of ACLF.

Sections du résumé

BACKGROUND BACKGROUND
Patients with liver cirrhosis often suffer from complications such as ascites, gastrointestinal bleeding, and infections, resulting in impaired quality of life. Frequently, the close relatives of patients also suffer from a lower quality of life in chronic diseases. In recent years, acute-to-chronic liver failure has been defined as a separate entity with high mortality. Often several organs are affected which makes intensive care therapy necessary. Little is known about the influence of acute-on-chronic-liver failure (ACLF) on the quality of life of patients and the psychosocial burden on close relatives.
AIM OBJECTIVE
The purpose of this prospective study is to investigate the influence of decompensated liver cirrhosis and the onset of ACLF of the patient's' quality of life and the psychosocial burden of close relatives.
METHOD METHODS
In this non - randomized prospective cohort study a total of 63 patients with acute decompensation of liver cirrhosis and hospital admission were enrolled in the study. To assess the quality of life of patients, the disease specific CLDQ questionnaire was assessed. In addition. Quality of life and psychosocial burden of first degree relatives was measured using the generic SF-36 questionnaire as well as the Zarit Burden Score.
RESULTS RESULTS
21 of the 63 patients suffered from ACLF. Patients with ACLF showed a lower quality of life in terms of worries compared to patients with only decompensated liver cirrhosis (3,57 ± 1,17 vs. 4,48 ± 1,27; p value: 0,008) and increased systemic symptoms (3,29 ± 1,19 vs. 4,48 ± 1,58; p value: 0,004). The univariate analysis confirmed the link between the existence of an ACLF and the concerns of patients. (p value: 0,001). The organ failure score was significantly associated with overall CLDQ scores, especially with worries and systemic symptoms of patients. Interestingly the psychosocial burden and quality of life of close relative correlates with patient's quality of life and was influenced by the onset of an acute-on-chronic liver failure.
CONCLUSION CONCLUSIONS
Patients with decompensated liver cirrhosis suffer from impaired quality of life. In particular, patients with ACLF have a significantly reduced quality of life. The extent of the psychosocial burden on close relative correlates with poor quality of life in patients with decompensated liver disease and is influenced by the existence of ACLF.

Identifiants

pubmed: 31931822
doi: 10.1186/s12955-019-1268-9
pii: 10.1186/s12955-019-1268-9
pmc: PMC6958780
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

10

Références

Psychogeriatrics. 2015 Jun;15(2):123-132
pubmed: 25521215
Am J Gastroenterol. 2011 Sep;106(9):1646-53
pubmed: 21556040
Clin Transl Gastroenterol. 2017 Jul 27;8(7):e108
pubmed: 28749453
Ann Gastroenterol. 2015 Jan-Mar;28(1):124-129
pubmed: 25608915
BMC Med. 2014 Sep 18;12:145
pubmed: 25242656
Aliment Pharmacol Ther. 2019 Feb;49(3):321-330
pubmed: 30585338
Eur J Oncol Nurs. 2015 Aug;19(4):376-82
pubmed: 25795160
J Clin Nurs. 2016 Sep;25(17-18):2559-68
pubmed: 27167534
Curr Gastroenterol Rep. 2002 Feb;4(1):79-83
pubmed: 11825545
Gut. 2017 Mar;66(3):541-553
pubmed: 28053053
Drugs. 2019 Feb;79(Suppl 1):11-16
pubmed: 30706419
Clin Exp Hepatol. 2018 Dec;4(4):232-239
pubmed: 30603670
Gastroenterology. 2001 Jan;120(1):170-8
pubmed: 11208726
J Neurol. 2018 Apr;265(4):793-808
pubmed: 29396678
Qual Life Res. 2008 May;17(4):575-84
pubmed: 18389385

Auteurs

Michael Nagel (M)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany. michael.nagel@unimedizin-mainz.de.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. michael.nagel@unimedizin-mainz.de.

Christian Labenz (C)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Marcus A Wörns (MA)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

J U Marquardt (JU)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Lichtenberg Research Group for Molecular Hepatocarcinogenesis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Peter R Galle (PR)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Jörn M Schattenberg (JM)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.
Metabolic Liver Research Program, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.

Marc Nguyen-Tat (M)

First Department of Medicine, University Medical Center Mainz of the Johannes Gutenberg-University Mainz, Langenbeckstrasse 1, 55131, Mainz, Germany. marc.nguyen-tat@klinikum-os.de.
Cirrhosis Center Mainz (CCM), University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany. marc.nguyen-tat@klinikum-os.de.
Medical Center Osnabrück, Department of Internal Medicine II, Am Finkenhügel 1, 49076, Osnabrück, Germany. marc.nguyen-tat@klinikum-os.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH